Artal Group’s Forte Biosciences FBRX Stock Holding History

Artal Group’s Portfolio FBRX Stock Details FBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-267	Closed	-$934K	–	111
2018 Q2	$934K	Hold	267	–	–	0.02%	99
2018 Q1	$1.19M	Hold	267	–	–	0.01%	101
2017 Q4	$1.02M	Buy	+267	New	+$1.07M	0.02%	112

Other funds holding FBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Artal Group's FBRX Position: Q3 2018 in Review

Artal Group sold out of Forte Biosciences (FBRX) in Q3 2018, closing a stake of 267 shares — an estimated $934K sold.

Artal Group first reported a position in FBRX in Q4 2017 and held it in 3 quarters. The position peaked at $1.19M in Q1 2018. 63 funds tracked by Wall St. Rank hold FBRX as of Q3 2018.

Artal Group reported no remaining Forte Biosciences position as of Q3 2018 after selling out during the quarter.
Artal Group sold 267 Forte Biosciences shares in Q3 2018, an estimated $934K.
Artal Group first reported a position in Forte Biosciences in Q4 2017 and held it in 3 quarters.
Artal Group's Forte Biosciences position peaked at $1.19M in Q1 2018.
63 funds tracked by Wall St. Rank held Forte Biosciences as of Q3 2018.

Based on Artal Group's 13F filing for Q3 2018, filed 9 Nov 2018.